148 related articles for article (PubMed ID: 6940656)
1. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
Casper ES; Gralla RJ; Young CW
Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of aclacinomycin A.
Van Echo DA; Whitacre MY; Aisner J; Applefeld MM; Wiernik PH
Cancer Treat Rep; 1982 May; 66(5):1127-32. PubMed ID: 6952961
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
4. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
5. [Intravesical instillation therapy of aclacinomycin-A (ACM) for superficial bladder tumor].
Noguchi S; Kubota Y; Shuin T; Miura T; Moriyama M; Sakuramoto T; Oshima H
Hinyokika Kiyo; 1984 Sep; 30(9):1153-8. PubMed ID: 6596878
[TBL] [Abstract][Full Text] [Related]
6. Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity.
Aabo K; Mortensen SA; Skovsgaard T; Gymoese E
Cancer Treat Rep; 1983 Mar; 67(3):281-2. PubMed ID: 6572564
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of aclacinomycin-A in head and neck cancer].
Tsukuda M
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2335-41. PubMed ID: 6594077
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.
Schütte J; Niederle N; Seeber S
J Cancer Res Clin Oncol; 1983; 105(2):162-5. PubMed ID: 6572190
[TBL] [Abstract][Full Text] [Related]
10. A phase of I trial of 4'-epi-Adriamycin.
Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW
Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126
[TBL] [Abstract][Full Text] [Related]
11. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
13. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.
Stanton GF; Raymond V; Wittes RE; Schulman P; Budman D; Baratz R; Williams L; Petroni GR; Geller NL; Hancock C
Cancer Res; 1985 Apr; 45(4):1862-8. PubMed ID: 3978646
[TBL] [Abstract][Full Text] [Related]
14. Experimental and clinical studies on aclarubicin in the treatment of solid tumors.
Kumai K; Kubota T; Ishibiki K; Abe O
Biomed Pharmacother; 1984; 38(7):332-7. PubMed ID: 6596963
[TBL] [Abstract][Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of aclacinomycin A.
Ogawa M; Inagaki J; Horikoshi N; Inoue K; Chinen T; Ueoka H; Nagura E
Cancer Treat Rep; 1979 May; 63(5):931-4. PubMed ID: 455335
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of aclacinomycin A (ACM-A, NSC208734) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey G
Am J Clin Oncol; 1983 Apr; 6(2):187-90. PubMed ID: 6572470
[TBL] [Abstract][Full Text] [Related]
20. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
Warrell RP
Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
